Pheast Therapeutics
- Biotech or pharma, therapeutic R&D
Pheast Therapeutics is focusing on novel macrophage immunotherapy drugs. Our lead program PHST001 is an antibody targeting CD24, a potent immune suppressive receptor that is highly expressed by a number of solid tumors.
We have started a Phase 1 clinical trial of PHST00 We have solid preclinical data showing synergies between PHST001 and chemotherapies, radiation therapies and ADCS .
We also have a discovery platform that has enabled drug discovery for multiple novel immune regulators, which we are deploying using different frameworks, including ADCs, in a distinct set of indications from our lead program.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}